Adaptive Clinical Trial Design: An Overview and Potential Applications in Dermatology

Journal of Investigative Dermatology

Volumn 136, Issue 7, 2016, Pages 1325-1329

  Merola, Joseph F ^a,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c TUFTS MEDICAL CENTER   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DERMATOLOGY; DOSE CALCULATION; DRUG COST; DRUG DESIGN; DRUG EFFECT; FOOD AND DRUG ADMINISTRATION; HUMAN; MAXIMUM TOLERATED DOSE; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; STUDY DESIGN; CLINICAL TRIAL (TOPIC); MEDICAL ETHICS; METHODOLOGY; PROCEDURES; SAMPLE SIZE; SKIN DISEASES; UNITED STATES;

CLINICAL TRIALS AS TOPIC; DERMATOLOGY; DRUG DESIGN; ETHICS, MEDICAL; HUMANS; RESEARCH DESIGN; SAMPLE SIZE; SKIN DISEASES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84992520066     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1016/j.jid.2016.02.807     Document Type: Review

References (28)

1. Barker, A.D., Sigman, C.C., Kelloff, G.J., Hylton, N.M., Berry, D.A., Esserman, L.J., I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 86 (2009), 97–100.
2. Bhatt, D.L., Stone, G.W., Mahaffey, K.W., Gibson, C.M., Steg, P.G., Hamm, C.W., et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med 368 (2013), 1303–1313.
3. Booth, B., Zemmel, R., Prospects for productivity. Nature Rev Drug Discov 3 (2004), 451–456.
4. Brannath, W., Koenig, F., Bauer, P., Multiplicity and flexibility in clinical trials. Pharm Stat 6 (2007), 205–216.
5. Bretz, F., Schmidl, H., Konig, F., Racine, A., Maurer, W., Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: general concepts. Biom J 48 (2006), 623–634.
6. Burton, A., Altman, D.G., Royston, P., Holder, R.L., The design of simulation studies in medical statistics. Stat Med 24 (2006), 4279–4292.
7. Chow, S.C., Chang, M., Adaptive design methods in clinical trials. 2007, Chapman & Hall/CRC, Boca Raton, FL.
8. Chow, S.C., Chang, M., Adaptive design methods in clinical trials. 2011, Chapman & Hall/CRC, New York.
9. Chow, S.C., Adaptive clinical trial design. Annu Rev Med 65 (2014), 405–415.
10. Chow, S.C., Chang, M., Pong, A., Statistical consideration of adaptive methods in clinical development. J Biopharm Stat 15 (2005), 575–591.
11. Coffey, C.S., Kairalla, J.A., Adaptive clinical trials: progress and challenges. Drugs R D 9 (2008), 229–242.
12. Gallo, P., Chuang-Stein, C., Dragalin, V., Gaydos, B., Krams, M., Pinheiro, J., Adaptive designs in clinical drug development: an executive summary of the PhRMA working group. J Biopharm Stat 16 (2006), 275–283.
13. Gu, X., Lee, J.J., A simulation study for comparing testing statistics in response-adaptive randomization. BMC Med Res Methadol 10 (2010), 48–62.
14. Jennison, C., Turnbull, B.W., Group sequential methods. 2000, Chapman & Hall/CRC, Boca Raton, FL.
15. Kairalla, J.A., Coffey, C.S., Thomann, M.A., Muller, K.E., Adaptive trial designs: a review of barriers and opportunities. Trials, 13, 2012, 145.
16. Kola, I., Landis, J., Can the pharmaceutical industry reduce attrition rates?. Nature Rev Drug Disc 3 (2004), 711–716.
17. Korn, E.L., Freidlin, B., Outcome-adaptive randomization: is it useful?. J Clin Oncol 29 (2011), 771–776.
18. Krams, M., Burman, C.F., Dragalin, V., Gaydos, B., Grieve, A.P., Pinheiro, J., et al. Adaptive designs in clinical drug development: opportunities, challenges, and scope reflections following PhRMA's November 2006 workshop. J Biopharm Stat 17 (2007), 957–964.
19. Leaute-Labreze, C., Hoeger, P., Mazereeuw-Hautier, J., Guibaud, L., Baselga, E., Posiunas, G., A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med 372 (2015), 735–746.
20. Maca, J., Bhattacharya, S., Dragalin, V., Gallo, P., Krams, M., Adaptive seamless phase II/III designs: background operational aspects and examples. Drug Inf J 40 (2006), 463–473.
21. Mehta, C.R., Patel, N.R., Adaptive group sequential and decision theoretic approaches to sample size determination. Stat Med 25 (2006), 3250–3269.
22. Orloff, J., Douglas, F., Pinheiro, J., Levinson, S., Branson, M., Chaturvedi, P., et al. The future of drug development: advancing clinical trial design. Nat Rev Drug Discov 8 (2009), 949–957.
23. Proschan, M.A., Sample size re-estimation in clinical trials. Biom J 51 (2009), 348–357.
24. Stallard, N., Todd, S., Seamless phase II/III designs. Stat Methods Med Res 20 (2011), 632–634.
25. Tamura, R.N., Krischer, J.P., Pagnoux, C., Micheletti, R., Grayson, P.C., Chen, Y.F., et al. A small n sequential multiple assignment randomized trial design for use in rare disease research. Contemp Clin Trials 46 (2016), 48–51.
26. US Food and Drug Administration: Draft Guidance for Industry: Adaptive Design Clinical Trials for Drugs and Biologics; 2010. Available at: https://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidance/UCM201790.pdf (accessed 10 October 2015).
27. Yuan, Y., Huang, X., Liu, S.A., Bayesian response-adaptive covariate-balanced randomization design with application to a leukemia clinical trial. Stat Med 30 (2011), 1218–1229.
28. Zumla, A., Nahid, P., Colse, S.T., Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov 12 (2013), 388–404.